Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.

导出 OA

翻译打印收藏纠错

第一作者： Samantha M,Steele

第一单位： Department of Pharmacy Practice, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.

作者： Samantha M,Steele ^[1] ; Anthony Thomas,Gerlach ^[2] ; Jessica L,Elefritz ^[3] ; Heena H,Sadaqat ^[1] ; Megan K,Phelps ^[3]

作者单位： Department of Pharmacy Practice, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA. ^[1] Department of Pharmacy Practice, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.;Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. ^[2] Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. ^[3]

关键词 adverse effects bradycardia coronavirus disease of 2019 remdesivir severe acute respiratory syndrome coronavirus 2

DOI 10.4103/ijciis.ijciis_57_24

PMID 39811032

发布时间 2025-01-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

International journal of critical illness and injury science

203-207页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.

International journal of critical illness and injury science

相似文献

International journal of critical illness and injury science

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.

International journal of critical illness and injury science

相似文献

International journal of critical illness and injury science

相关期刊

检索历史清除